Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Activate Rutherrin(R) At Home
View:
Post by made2last on Aug 21, 2024 7:39am

Activate Rutherrin(R) At Home

Hi all;

Activate Rutherrin(R) At Home. Game changer. IV at home, followed by taking a pill, Metformin.
Read link below!

Thanks;

made2last


https://stockhouse.com/news/press-releases/2024/08/21/theralase-r-demonstrates-unique-ability-to-activate-rutherrin-r-with-diabetes

Comment by Legit62 on Aug 21, 2024 7:43am
Freaken brilliant, $100 a share in the making
Comment by enriquesuave on Aug 21, 2024 7:58am
Awesome news!  The versatility of our drug keeps on increasing!  The ROS production of Rutherin plus mefformin combo is equivalent to the ROS of irradiated Ruherin alone!  Wow!
Comment by Oilminerdeluxe on Aug 21, 2024 8:04am
These sound cool. "The ability to activate Rutherrin®, with commonly available drugs like Metformin, significantly opens the clinical applications of Rutherrin®, in the destruction of various cancers. Rutherrin®" " The clear advantage is that light and/or radiation equipment is no longer a prerequisite and the procedure can be completed outside of the hospital ...more  
Comment by hilles on Aug 21, 2024 8:06am
Maybe the response was better with some People because they use metformin. A lot of individuals use that mdication.
Comment by Oilminerdeluxe on Aug 21, 2024 8:10am
Hope Roger talks about it today!
Comment by DeathXray33 on Aug 22, 2024 6:15pm
A "reduction in the risk of" ??? Hmmm... ------------------------------------------------------------ August 22, 2024 --------------------------------- Health Canada Approves KEYTRUDA for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination with enfortumab vedotin------------------- ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250